Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
DaVita (DVA)
NYSE:DVA
DaVita (DVA) Stock Price & Analysis
868 Followers
DVA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$71.51 - $145.04
Previous Close$143.67
Volume1.22M
Average Volume (3M)809.49K
Market Cap
$12.60B
Enterprise Value$25.01B
Total Cash (Recent Filing)$391.67M
Total Debt (Recent Filing)$11.12B
Price to Earnings (P/E)16.3
Beta0.31
Next Earnings
Aug 01, 2024EPS Estimate
$2.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.81
Shares Outstanding87,700,000
10 Day Avg. Volume826,470
30 Day Avg. Volume809,494
Standard Deviation0.10
R-Squared0.28
Alpha0.00995
Financial Highlights & Ratios
Price to Book (P/B)-1.94
Price to Sales (P/S)4.00
Price to Cash Flow (P/CF)6.30
P/FCF Ratio8.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.06
Enterprise Value/Gross Profit6.55
Enterprise Value/Ebitda11.82
Forecast
1Y Price Target
$143.50Price Target Upside-2.17% Downside
Rating ConsensusHold
Number of Analyst Covering4
DaVita News
PremiumMarket News
SPY ETF Update, 5/3/2024 
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsStudy found that patients in the semaglutide group had CKD progression slowed by about 27% compared to the placebo group, alongside a 20% reduction in all-cause mortality, which aligns with expectations and suggests a favorable outlook for long-term use.
Financial PerformanceImprovement in revenue per treatment is being driven by inflation adjustments in Medicare rates and commercial repricing, indicating a stronger financial position.
Operational EfficiencyEfforts to improve capacity utilization and stabilize the labor market are anticipated to reduce costs and improve margins, potentially enhancing overall profitability.
Bears Say
Earnings ForecastEstimated loss of $37m of EBITDA in 2025 for DaVita Inc. due to the new CMS rates.
Regulatory ImpactSurprise hit to dialysis buried in CMS Final Rates for 2025 MA and Part D could impact DaVita Inc.'s revenues.
Stock ValuationApproximate $3.49 impact to the share price based on the 2025E P/E ratio due to CMS rate changes.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
DVA FAQ
What was DaVita’s price range in the past 12 months?
DaVita lowest stock price was $71.51 and its highest was $145.04 in the past 12 months.
What is DaVita’s market cap?
Currently, no data Available
When is DaVita’s upcoming earnings report date?
DaVita’s upcoming earnings report date is Aug 01, 2024 which is in 63 days.
How were DaVita’s earnings last quarter?
DaVita released its earnings results on May 02, 2024. The company reported $2.38 earnings per share for the quarter, beating the consensus estimate of $1.948 by $0.432.
Is DaVita overvalued?
According to Wall Street analysts DaVita’s price is currently Overvalued.
Does DaVita pay dividends?
DaVita does not currently pay dividends.
What is DaVita’s EPS estimate?
DaVita’s EPS estimate is $2.55.
How many shares outstanding does DaVita have?
DaVita has 87,700,000 shares outstanding.
What happened to DaVita’s price movement after its last earnings report?
DaVita reported an EPS of $2.38 in its last earnings report, beating expectations of $1.948. Following the earnings report the stock price went down -5.477%.
Which hedge fund is a major shareholder of DaVita?
Among the largest hedge funds holding DaVita’s share is Berkshire Hathaway Inc. It holds DaVita’s shares valued at 5B.
---
DaVita Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$143.50 (-2.17% Downside)
$143.50 (-2.17% Downside)
Blogger Sentiment
Bullish
DVA Sentiment 92%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 454.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $698.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 5.4%
Last 30 Days ▲ 5.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
52.38%
12-Months-Change
Fundamentals
Return on Equity
93.14%
Trailing 12-Months
Asset Growth
4.20%
Trailing 12-Months
Company Description
DaVita
DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services; and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.
---
DVA Earnings Call
Q1 2024
0:00 / 0:00
---
DVA Revenue Breakdown
95.34% U.S. dialysis
4.66% Ancillary services
---
DVA Stock 12 Month Forecast
Average Price Target
$143.50
▼(-2.17% Downside)
Technical Analysis
Best Analysts Covering DVA
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-35.01%
reiterated a sell rating 15 days ago
Copying Kevin Fischbeck's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -35.01% per trade.
---